Challenges Associated With Molecular Targeted Therapies in Lung Cancer

Thomas J. Lynch, MD, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

Clinical Pearls

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

  • It is important for an oncologist to know when use (or switch) molecular targeted therapies in relation to a patient’s degree of progression.
  • Dealing with drug side effects remains a challenge. During later lines of treatment, patients are typically less tolerant of side effects.